DE69940774D1 - Hla-bindende peptide und ihre verwendungen - Google Patents

Hla-bindende peptide und ihre verwendungen

Info

Publication number
DE69940774D1
DE69940774D1 DE69940774T DE69940774T DE69940774D1 DE 69940774 D1 DE69940774 D1 DE 69940774D1 DE 69940774 T DE69940774 T DE 69940774T DE 69940774 T DE69940774 T DE 69940774T DE 69940774 D1 DE69940774 D1 DE 69940774D1
Authority
DE
Germany
Prior art keywords
hla
peptides
binding peptides
immunogenic
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940774T
Other languages
German (de)
English (en)
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOTECH SYNERGY, INC., US
Original Assignee
IDM Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IDM Pharma Inc filed Critical IDM Pharma Inc
Application granted granted Critical
Publication of DE69940774D1 publication Critical patent/DE69940774D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69940774T 1998-06-17 1999-06-17 Hla-bindende peptide und ihre verwendungen Expired - Lifetime DE69940774D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9858498A 1998-06-17 1998-06-17
PCT/US1999/013789 WO1999065522A1 (en) 1998-06-17 1999-06-17 Hla binding peptides and their uses

Publications (1)

Publication Number Publication Date
DE69940774D1 true DE69940774D1 (de) 2009-06-04

Family

ID=22269985

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940774T Expired - Lifetime DE69940774D1 (de) 1998-06-17 1999-06-17 Hla-bindende peptide und ihre verwendungen

Country Status (8)

Country Link
EP (2) EP1089757B1 (enExample)
JP (2) JP2002518346A (enExample)
AT (1) ATE429247T1 (enExample)
AU (1) AU4577899A (enExample)
CA (1) CA2330824A1 (enExample)
DE (1) DE69940774D1 (enExample)
ES (1) ES2326146T3 (enExample)
WO (1) WO1999065522A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
EP1237564A4 (en) * 1999-12-10 2005-05-04 Epimmune Inc TRIGGERING OF CELLULAR IMMUNE RESPONSES AGAINST P53 USING NUCLEIC ACID AND PEPTIDE COMPOSITIONS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2919835A1 (en) 2013-07-31 2015-02-05 Board Of Trustees Of The University Of Arkansas Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69031305T2 (de) 1989-11-03 1998-03-26 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
JPH10510988A (ja) * 1994-12-14 1998-10-27 ザ スクリップス リサーチ インスティテュート 腫瘍−特異的細胞毒性ｔ細胞のインビボ活性化
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
DK0900380T3 (da) * 1996-04-26 2003-11-03 Seed Capital Investments Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper

Also Published As

Publication number Publication date
EP1089757A4 (en) 2002-10-30
AU4577899A (en) 2000-01-05
EP1089757B1 (en) 2009-04-22
ES2326146T3 (es) 2009-10-01
ATE429247T1 (de) 2009-05-15
CA2330824A1 (en) 1999-12-23
EP1089757A1 (en) 2001-04-11
EP2036573A1 (en) 2009-03-18
JP2002518346A (ja) 2002-06-25
WO1999065522A1 (en) 1999-12-23
JP2010090167A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
ATE536187T1 (de) Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
BR9406652A (pt) Composição
DE69334076D1 (de) Hla bindepeptide und ihre verwendungen
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
DK0941478T4 (da) Assaymetode for peptidspecifikke T-celler
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
DE69940774D1 (de) Hla-bindende peptide und ihre verwendungen
AU5963500A (en) Peptides for vaccinating against human cmv
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
DE60045776D1 (de) Hla-bindungspeptide und ihre anwendungszwecke
AU1598500A (en) Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
DK1230261T3 (da) NY-ESO-1 Nonapeptidderivater og anvendelser af disse
WO2004011483A3 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
ATE414717T1 (de) Neuromedin u delta polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1089757

Country of ref document: EP

Representative=s name: LEINWEBER & ZIMMERMANN, DE

R081 Change of applicant/patentee

Ref document number: 1089757

Country of ref document: EP

Owner name: BIOTECH SYNERGY, INC., US

Free format text: FORMER OWNER: IDM PHARMA, INC., IRVINE, US

Effective date: 20121016

R082 Change of representative

Ref document number: 1089757

Country of ref document: EP

Representative=s name: LEINWEBER & ZIMMERMANN, DE

Effective date: 20121016